Loading...
•
Sep 30, 2022
Atea Q3 2022 Earnings Report
Atea Pharmaceuticals reported financial results for Q3 2022 and provided a business update.
Key Takeaways
Atea Pharmaceuticals reported on their progress in advancing clinical candidates, with expectations of pivotal developments in 2023. They anticipate imminent enrollment into the SUNRISE-3 trial for COVID-19, completion of enrollment in the AT-752 challenge study and the first cohort of DEFEND-2, and submission of clinical trial applications for a Hepatitis C study.
Enrollment of patients into SUNRISE-3 evaluating bemnifosbuvir for COVID-19 is expected imminently.
Completion of enrollment is anticipated around the end of the year for the AT-752 challenge study and the first cohort of DEFEND-2, with initial data to follow.
Clinical trial applications for the bemnifosbuvir and ruzasvir combination hepatitis C study are expected to be submitted around year-end, leading to Phase 2 initiation.
Atea continues to progress its second-generation protease inhibitor discovery program for COVID-19, focused on candidates for combination therapy with bemnifosbuvir.
Forward Guidance
Atea Pharmaceuticals anticipates several key milestones in the near future, including the start of patient enrollment for the SUNRISE-3 trial, completion of enrollment for the AT-752 challenge study and DEFEND-2 trial's first cohort, and submission of clinical trial applications for the combination study of bemnifosbuvir and ruzasvir for Hepatitis C.
Positive Outlook
- Expect imminent enrollment of patients into SUNRISE-3 evaluating bemnifosbuvir for COVID-19.
- Anticipate completing enrollment in the AT-752 challenge study around the end of the year.
- Expect to complete enrollment in the first cohort of DEFEND-2 around the end of the year.
- Initial data from AT-752 challenge study and DEFEND-2 trial's first cohort is expected to follow completion of enrollment.
- Expect to submit clinical trial applications for the bemnifosbuvir and ruzasvir combination hepatitis C study around the end of the year, leading to Phase 2 initiation.
Challenges Ahead
- Uncertainty around and costs associated with the clinical development of bemnifosbuvir as a potential treatment for COVID-19.
- Uncertainty around and costs associated with the clinical development of bemnifosbuvir as a potential treatment for HCV.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...